We got the letter from the National Institutes for Health confirming the award of nearly $3 million to conduct clinical tests of PGXL’s PerMIT:Warfarin software. (Press release here.) PerMIT, which is short for “Personalized Medicine Interface Tool,” is a web-based software that enables physicians to input relevant patient data that, combined with genetic information from PGXL, postulates an optimal dosing strategy for patients beginning warfarin therapy.
There are, of course, plenty of warfarin dosing apps out there. What’s unique about PerMIT — and what we believe has led to the NIH support — is that it doesn’t just predict the ultimate dose a patient will require to maintain the desired INR. It plots a calendar of varying doses that will bring that specific patient to target INR as quickly and as safely as possible. That information is presented through an easy-to-understand graphic interface that changes in real time as additional information is input by the physician or lab.
PGXL has been providing genetic testing services for almost a decade, always pairing test results with interpretive consulting for physicians. As the field has grown, we can see that there’s a need for that consulting to “go mass,” to be available on demand to thousands of physicians on an economically sustainable basis. That’s why we developed PerMIT.
The NIH grant enables us to conduct clinical tests that will test whether PerMIT, applied in a real-world setting, actually gets warfarin patients to their target INR more quickly and safely than current best medical practices. We’ll keep you informed of the progress of those trials.